ScreenPoint Medical: AI-Enhanced Mammography Screening Significantly Improves Breast Cancer Detection and Reduces Radiologist Workload
Only randomized controlled trial of its kind highlights impact of Transpara Breast AI
Overcoming Challenges with Transpara
In addition to extensive clinical research published in peer reviewed journals, we are always excited to share insights gathered along the path of rigorous scientific study and clinical practice.
Only randomized controlled trial of its kind highlights impact of Transpara Breast AI
Deal brings enhanced capabilities for ScreenPoint’s industry-leading Transpara Breast AI.
Boxem reflects on how AI could have changed her cancer journey.
© 2025, ScreenPoint Medical BV. All rights reserved. Transpara® is a registered trademark of ScreenPoint Medical BV. Reproduction of any material contained herein in any format or media without express written permission of ScreenPoint Medical BV is prohibited. *Disclaimer: Transpara is CE marked and FDA cleared for 2D and 3D mammography. CE (0344) certified. FDA 510(k) K241831 and K232096. Not all features are available in all countries. Please check with local representatives.
Lake Medical Imaging Case Study
Download the study to see how Transpara reduces radiologist workload and improves diagnostic confidence.